- Tune Therapeutics has completed a $175M financing round led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation.
- The funding will accelerate the development of Tune’s existing pipeline, focusing on its lead clinical-stage program, Tune-401 for chronic Hepatitis B, and other epigenetic therapies.

Tune Therapeutics, a leading epigenome editing company, has secured over $175 million in financing to further the development of its innovative therapies targeting chronic and common diseases. The funding round was led by prominent investors including New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation.
The funds will support the advancement of Tune’s clinical-stage program, particularly Tune-401, an epigenetic silencing drug for chronic Hepatitis B (HBV). This condition affects over 250 million people worldwide and is a major cause of liver cancer. In addition to HBV, the financing will also support other gene, cell, and regenerative therapy programs under development at Tune.
Dr. Charles Gersbach, co-founder of Tune Therapeutics, expressed his gratitude for the support, highlighting the company’s progress in the field. “It is deeply gratifying to have seen this platform and company evolve so far,” said Gersbach. “Thanks to the support of our investors, we anticipate the development of many more new epi-editing therapies in the years to come.”
In 2023, Tune achieved a major milestone in the field by successfully repressing the PCSK9 gene in non-human primates, leading to a sustained reduction in LDL cholesterol. This breakthrough marked a global first for the company and underscored the potential of epigenetic editing as a therapeutic modality. Tune’s commitment to advancing its technology was further evidenced by the clinical progress of Tune-401, which has entered trials in New Zealand and Hong Kong.
Reed Jobs, Founder and Investor at Yosemite, expressed confidence in Tune’s potential, stating, “Few technologies have the biological power of epigenetic medicine to transform disease outcomes for the better.” With its pipeline now in clinical trials, Tune is poised to continue pushing the boundaries of epigenetic therapies, supported by strong investor confidence and promising early results.
“We are grateful to all our investors for their deep confidence in our team and approach,” added Akira Matsuno, Co-Founder and President of Tune Therapeutics. “This funding will enable us to accelerate our HBV clinical program and expand our pipeline of transformative therapies.”